|  |  |
| --- | --- |
| **Domain:** | Reproductive Health |
| **Measure:** | Human Papillomavirus Vaccine Use |
| **Definition:** | Questions to assess women's use of the human papillomavirus vaccine. |
| **Purpose:** | These questions ascertain if a woman received the human papillomavirus vaccine and if so, the number of doses received. Use of the vaccine impacts a woman's risk of developing cervical cancer and the overall incidence rate of cervical cancer. |
| **Essential PhenX Measures:** | Current Age Gender |
| **Related PhenX Measures:** |  |
| **Collections:** | Preventive Health Care Behavioral Cancer Risks Immunizations |
| **Keywords:** | Reproductive health, human papillomavirus, vaccination, infectious disease prevention, genital wart prevention, Behavioral Risk Factor Surveillance System (BRFSS), GARDASIL®, Silgard |

|  |  |
| --- | --- |
| **Protocol Release Date:** | February 26, 2010 |
| **PhenX Protocol Name:** | Human Papillomavirus Vaccine Use |
| **Protocol Name from Source:** | The Expert Review Panel has not reviewed this measure yet. |
| **Description:** | The interviewer asks the female participant whether she has ever received a human papillomavirus (HPV) vaccination. If she answers yes, the interviewer asks her age and how many shots she received. |
| **Specific Instructions:** | If the participant answers "yes" to question 1, the interviewer should complete the rest of the protocol. If the participant answers "no" then the protocol is deemed complete.  The PhenX Working Group notes that GARDASIL® is also known as Silgard.   * European Medicines Agency. (September 25, 2009). Silgard European Public Assessment Report. Retrieved from http://www.emea.europa.eu/humandocs/Humans/EPAR/silgard/silgard.htm. * Waknine, Yael. (October 2, 2006). International Approvals: Singulair and Gardasil/Silgard. Medscape Today. Retrieved from http://www.medscape.com/viewarticle/545374. |
| **Protocol:** | 1. A vaccine to prevent the human papilloma virus or HPV infection is available and is called cervical cancer vaccine, HPV shot, or GARDASIL®. Have you EVER had the HPV vaccination?  [ ] 1 Yes  [ ] 2 No (skip to end)  [ ] 3 Doctor refused when asked (skip to end)  [ ] 7 Don't know / Not sure (skip to end)  [ ] 9 Refused (skip to end)  2. If yes, what was your age when you were vaccinated?  3. How many HPV shots did you receive?  [ ] \_\_ Number of shots;  [ ] 0 All shots;  [ ] 7 Don't know/ Not sure;  [ ] 9 Refused  GARDASIL® is a registered trademark of Merck & Co., Inc.erck & Co., Inc. |
| **Selection Rationale:** | The Behavioral Risk Factor Surveillance System is telephone interview surveillance system sponsored by the Centers for Disease Control and Prevention gathering data in all 50 states and the District of Columbia. It introduced questions human papillomavirus (HPV) vaccine in 2009. As HPV vaccine has only recently been approved by the Food and Drug Administration (June 2006), earlier national surveys did not include the HPV vaccine in their protocols. |
| **Source:** | Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System (BRFSS) 2009. Module 16 Question 1 (question 1) and Question 2 (question 3).  New (question 2) which may be considered essential data. |
| **Life Stage:** | Adult |
| **Language of source:** | English |
| **Participant:** | GARDASIL® is approved by the FDA for use in females ages 9-26. BRFSS asks these questions to females ages 18-49. |
| **Personnel and Training Required:** | The interviewer must be trained to conduct personal interviews with individuals from the general population. The interviewer must be trained and found to be competent (i.e., tested by an expert) at the completion of personal interviews. |
| **Equipment Needs:** | Paper and pencil |
| **Standards:** | |  |  |  |  | | --- | --- | --- | --- | | **Standard** | **Name** | **ID** | **Source** | | Common Data Element (CDE) | Person Human Papillomavirus Vaccine Use | 3007465 | [CDE Browser](https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&FirstTimer=0&PageId=ElementDetailsGroup&publicId=3007465&version=1.0) | | Logical Observation Identifiers Names and Codes (LOINC) | HPV vaccine use proto | 62662-2 | [LOINC](http://s.details.loinc.org/LOINC/62662-2.html?sections=Web) | |
| **General references:** | Tiro JA, Saraiya M, Jain N, Liddon N, Cokkinides V, Lai SM, et al. (2008). Human papillomavirus and cervical cancer behavioral surveillance in the US. Cancer, 113(10 Suppl):3013-30. Review. PubMed PMID: 18980284.  Christian WJ, Christian A, Hopenhayn C. (2009). Acceptance of the HPV vaccine for adolescent girls: analysis of state-added questions from the BRFSS. J Adolesc Health, 44(5):437-45. Epub 2008 Oct 31. PubMed PMID: 19380090. |
| **Mode of Administration:** | Interviewer-administered questionnaire |
| **Derived Variables:** | None |
| **Requirements:** | |  |  | | --- | --- | | **Requirement Category** | **Required** | | Major equipment | No | | Specialized training | No | | Specialized requirements for biospecimen collection | No | | Average time of greater than 15 minutes in an unaffected individual | No | |
| **Process and Review:** | The Expert Review Panel has not reviewed this measure yet. |